Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Steger

Showing results (261-270 of 320) with videos related to

Pageof 32
Sort By:
Breast Cancer Research and Treatment|January 2, 2004
Influence of neoadjuvant therapy with epirubicin and docetaxel on the expression of HER2/neu in patients with breast cancerSusanne Taucher, Margaretha Rudas, Robert M Mader, et al.
Anti-Cancer Drugs|January 19, 2005
Single-agent trastuzumab versus trastuzumab plus cytotoxic chemotherapy in metastatic breast cancer: a single-institution experienceWolfgang J Köstler, Günther G Steger, Michael Krainer, et al.
Breast (Edinburgh, Scotland)|July 15, 2014
Co-overexpression of HER2/HER3 is a predictor of impaired survival in breast cancer patientsAnna S Berghoff, Rupert Bartsch, Matthias Preusser, et al.
British Journal of Cancer|July 23, 2013
The predictive impact of body mass index on the efficacy of extended adjuvant endocrine treatment with anastrozole in postmenopausal patients with breast cancer: an analysis of the randomised ABCSG-6a trialM Gnant, G Pfeiler, H Stöger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 24, 1999
Randomized trial of low-dose chemotherapy added to tamoxifen in patients with receptor-positive and lymph node-positive breast cancerR Jakesz, H Hausmaninger, K Haider, et al.
Onkologie|May 29, 2003
Randomised trial: One cycle of anthracycline-containing adjuvant chemotherapy compared with six cycles of CMF treatment in node-positive, hormone receptor-negative breast cancer patientsF Ploner, R Jakesz, H Hausmaninger, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 12, 2004
Monitoring of serum Her-2/neu predicts response and progression-free survival to trastuzumab-based treatment in patients with metastatic breast cancerWolfgang J Köstler, Barbara Schwab, Christian F Singer, et al.
Cancer Chemotherapy and Pharmacology|February 15, 2014
BRCA-1 methylation and TP53 mutation in triple-negative breast cancer patients without pathological complete response to taxane-based neoadjuvant chemotherapyMathilde Foedermayr, Miriam Sebesta, Margaretha Rudas, et al.
British Journal of Cancer|December 1, 2011
Impact of anti-HER2 therapy on overall survival in HER2-overexpressing breast cancer patients with brain metastasesR Bartsch, A Berghoff, U Pluschnig, et al.
The Lancet. Oncology|January 15, 2013
Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trialIstvan Lang, Thomas Brodowicz, Larisa Ryvo, et al.
Pageof 32

Showing results (261-270 of 320) with videos related to

Sort By:
Pageof 32
Breast Cancer Research and Treatment|January 2, 2004
Influence of neoadjuvant therapy with epirubicin and docetaxel on the expression of HER2/neu in patients with breast cancerSusanne Taucher, Margaretha Rudas, Robert M Mader, et al.
Anti-Cancer Drugs|January 19, 2005
Single-agent trastuzumab versus trastuzumab plus cytotoxic chemotherapy in metastatic breast cancer: a single-institution experienceWolfgang J Köstler, Günther G Steger, Michael Krainer, et al.
Breast (Edinburgh, Scotland)|July 15, 2014
Co-overexpression of HER2/HER3 is a predictor of impaired survival in breast cancer patientsAnna S Berghoff, Rupert Bartsch, Matthias Preusser, et al.
British Journal of Cancer|July 23, 2013
The predictive impact of body mass index on the efficacy of extended adjuvant endocrine treatment with anastrozole in postmenopausal patients with breast cancer: an analysis of the randomised ABCSG-6a trialM Gnant, G Pfeiler, H Stöger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 24, 1999
Randomized trial of low-dose chemotherapy added to tamoxifen in patients with receptor-positive and lymph node-positive breast cancerR Jakesz, H Hausmaninger, K Haider, et al.
Onkologie|May 29, 2003
Randomised trial: One cycle of anthracycline-containing adjuvant chemotherapy compared with six cycles of CMF treatment in node-positive, hormone receptor-negative breast cancer patientsF Ploner, R Jakesz, H Hausmaninger, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 12, 2004
Monitoring of serum Her-2/neu predicts response and progression-free survival to trastuzumab-based treatment in patients with metastatic breast cancerWolfgang J Köstler, Barbara Schwab, Christian F Singer, et al.
Cancer Chemotherapy and Pharmacology|February 15, 2014
BRCA-1 methylation and TP53 mutation in triple-negative breast cancer patients without pathological complete response to taxane-based neoadjuvant chemotherapyMathilde Foedermayr, Miriam Sebesta, Margaretha Rudas, et al.
British Journal of Cancer|December 1, 2011
Impact of anti-HER2 therapy on overall survival in HER2-overexpressing breast cancer patients with brain metastasesR Bartsch, A Berghoff, U Pluschnig, et al.
The Lancet. Oncology|January 15, 2013
Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trialIstvan Lang, Thomas Brodowicz, Larisa Ryvo, et al.
Pageof 32